June 17th 2021, 1:00pm
Novel combo regimen reduces number of toxic treatments in patients with NSCLC.
June 16th 2021, 3:21pm
Common questions asked by patients with lung or thyroid cancer who have been referred for biomarker testing and advice for setting expectations from test results.
June 16th 2021, 3:15pm
Drs Benjamin Levy and Lori J. Wirth comment on the current role of liquid biopsies in lung and thyroid cancer.
June 9th 2021, 2:45pm
Recommendations for selecting appropriate patients for comprehensive genomic profiling and navigating through the testing process.
June 9th 2021, 2:35pm
Drs Benjamin Levy and Lori J. Wirth describe how they currently utilize comprehensive genomic profiling to manage patients with non–small cell lung cancer or thyroid cancer.
June 8th 2021, 1:00pm
Combination of Opdivo and Yervoy had improved efficacy and durable response after four years in patients with advanced non-small cell lung cancer.
June 8th 2021, 12:00pm
Mobocertinib showed clinically meaningful benefits in patients with EGFR exon 20 insertion–positive metastatic non-small cell lung cancer with a manageable safety profile.
June 7th 2021, 8:00pm
In a final analysis of a study examining the effectiveness of Alecensa compared to Xalkori in patients with non-small cell lung cancer, the Alecensa-treated group did not achieve better survival outcomes.
June 7th 2021, 1:00pm
The long-term follow-up data, according to one of the study’s authors from the Sarah Cannon Cancer Institute, demonstrate “a new benchmark for the standard of care” in the treatment of patients with unresectable stage 3 non-small cell lung cancer.
June 7th 2021, 12:00pm
Treatment with aumolertinib was associated with prolonged survival in patients with advanced non-small cell lung cancer.
A Milkshake and Metastatic Cancer
Fighting Hard for Patients with Fibrolamellar Carcinoma
Masking in a ‘Post-Pandemic’ World
A Guardian Angel Among Doctors
